AI Article Synopsis
- Mycoplasma hyopneumoniae (Mhp) is responsible for Mycoplasmal pneumonia of swine (MPS), leading to significant losses in the swine industry globally.
- Current vaccination methods, including inactivated and attenuated live vaccines, are the primary prevention strategies but have notable limitations.
- The review highlights recent advancements in vaccine development, especially focusing on genetically engineered and novel combined vaccines targeting the adhesion factors of Mhp for improved efficacy.
Article Abstract
Mycoplasma hyopneumoniae (Mhp) is the pathogen of Mycoplasmal pneumonia of swine (MPS), a chronic respiratory infectious discease which causes enormous losses to the swine industry worldwide. At present, vaccination is the most effective mean to prevent and reduce economic losses caused by this pathogen. Currently, MPS vaccines mainly include inactivated vaccines and attenuated live vaccines. However, these approved vaccines still have many drawbacks, and the infection of Mhp has not yet been fully elucidated. Adhesion factors of Mhp have been shown to play a direct role in the pathogen's adherence, and thus were given consideration to be included in the composition of the vaccine. This shows a good prospect due to the advantages and feasibility of genetically engineering a vaccine. In this review, we summarize the work of researchers in recent years about the development of vaccines against Mhp, and we focus on the development of genetically engineering vaccines and some novel combined vaccines.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.rvsc.2019.01.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!